Service analysis about transformation of scientific and technological achievements in diagnosis of tuberculosis in vitro

doi:10.19982/j.issn.1000-6621.20240048

Abstract

Abstract:

A definitive diagnosis is paramount for effective tuberculosis (TB) prevention and treatment. Early and accurate diagnosis is crucial for timely treatment of TB patients, while advancements in diagnostic technologies are essential for effectively identifying patients. The In Vitro diagnostic (IVD) products for TB boasts a vast market and strong clinical demand. However, current challenges persist. Basic research and development often fall short of meeting clinical needs, and the pool of diagnostic-related patent technical achievements remains limited. Ongoing technical breakthroughs are essential to address these gaps. Existing diagnostic products often lack the versatility to meet the full spectrum of clinical needs. To drive rapid growth in the TB IVD industry and bolster prevention and control efforts, comprehensive service offerings are required across the entire technology development lifecycle—from achievement to productization and commercialization.

Key words: Tuberculosis, Diagnostic techniques, respiratory system, Transformation of scientific and technological achievement, Service analysis

CLC Number:

R52
R197.323

Zhang Hongjing, Chu Hongqian, Sun Zhaogang, Xie Zhongyao. Service analysis about transformation of scientific and technological achievements in diagnosis of tuberculosis in vitro[J]. Chinese Journal of Antituberculosis, 2024, 46(7): 743-749. doi: 10.19982/j.issn.1000-6621.20240048

Figures/Tables 4

References 24

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1): 15-19. doi:10.19983/j.issn.2096-8493.2024006.
[2]	Uplekar M, Weil D, Lonnroth K, et al. WHO’s new end TB strategy. Lancet (London, England), 2015, 385(9979):1799-1801. doi:10.1016/S0140-6736(15)60570-0.
[3]	新华社. 金砖国家领导人厦门宣言[EB/OL]. [2017-09-04]. https://www.gov.cn/xinwen/2017-09/04/content_5222643.htm.
[4]	World Health Organization. Moscow Declaration to End TB.[EB/OL]. [2017-11-17]. https://www.who.int/publications/i/item/WHO-HTM-TB-2017.11.
[5]	国务院办公厅. 国务院办公厅关于印发“十三五”全国结核病防治规划的通知.国办发〔2017〕16号.2017-02-01.
[6]	Zhang L, Zhang Y, Shi X, et al. Utility of T-cell interferon-γ release assays for diagnosing tuberculous serositis: a prospective study in Beijing, China. PLoS One, 2014, 9(1):e85030. doi:10.1371/journal.pone.0085030.
[7]	Guenaoui K, Harir N, Ouardi A, et al. Use of GeneXpert Mycobacterium tuberculosis/rifampicin for rapid detection of rifampicin resistant Mycobacterium tuberculosis strains of clinically suspected multi-drug resistance tuberculosis cases. Ann Transl Med, 2016, 4(9):168. doi:10.21037/atm.2016.05.09. pmid: 27275481
[8]	Kohli M, Schiller I, Dendukuri N, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev, 2021, 1(1):CD012768. doi:10.1002/14651858.CD012768.pub3.
[9]	贝哲斯咨询. 2023—2029年中国结核病(TB)诊断行业整体及细分市场研究报告.GMM1687708. 2023-02-09.
[10]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 3: Diagnosis-Tests for tuberculosis infection. Geneva: World Health Organization, 2022.
[11]	Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis, 2006, 6(10):664-674. doi:10.1016/S1473-3099(06)70602-8. pmid: 17008175
[12]	Styrt BA, Shinnick TM, Ridderhof JC, et al. Turnaround times for mycobacterial cultures. J Clin Microbiol, 1997, 35(4):1041-1042. doi:10.1128/jcm.35.4.1041-1042.1997.
[13]	国家药品监督管理局. 结核医疗器械注册数据查询[DB/OL].[2024-01-20]. https://www.nmpa.gov.cn/datasearch/searchresult.html.
[14]	World Health Organization. ZH mediacentre PR 2011: WHO warns against the use of inaccurate blood tests for active tuberculosis. Geneva: World Health Organization, 2011.
[15]	Rajendran P, Padmapriyadarsini C, Nair S, et al. Newer TB diagnostics: An update. Indian J Tuberc, 2023, 70(3):372-375. doi:10.1016/j.ijtb.2023.04.019. pmid: 37562916
[16]	陈福军, 何乐春, 李非. 物联网在体外诊断试剂的研发、生产、质量管理方面的应用. 中国医疗器械信息, 2018, 24(19):61-64. doi:10.3969/j.issn.1006-6586.2018.19.022.
[17]	中国防痨协会第十二届理事会. 九十载砥砺奋进展未来似锦前程. 中国防痨杂志, 2023, 45(11): 1011-1015. doi:10.19982/j.issn.1000-6621.20230363.
[18]	范瑞泉, 宗晓琳, 方丽, 等. 卫生与健康科技成果转化现状与对策. 中国职业医学, 2023, 50(2):194-199. doi:10.20001/j.issn.2095-2619.20230415.
[19]	陈宁, 赵露, 陈雨生. 海洋国家实验室科技成果转化服务体系研究. 科技管理研究, 2019, 39(11):122-128. doi:10.3969/j.issn.1000-7695.2019.11.017.
[20]	赵琼姝, 王晓玲, 邰隽, 等. 国家重大新药创制专项课题管理系统设计. 中国卫生信息管理杂志, 2021, 18(2):208-213. doi:10.3969/j.issn.1672-5166.2021.02.012.
[21]	曹烨. 哈佛医学院DF/HCC临床研究管理介绍——临床研究项目的“全流程”管理. 中国新药杂志, 2015, 24(10):1096-1099.
[22]	杨山石, 何阿妹, 金春林. 上海两大高校医学院医学领域主要专利竞争差异与对标发展路径. 中国卫生资源, 2022, 25(4):507-514. doi:10.3969/j.issn.1007-953X.2022.04.022.
[23]	彭圣贤, 刘悦, 邱菊, 等. 医药卫生健康领域科技成果转化现状与对策. 中国科技信息, 2022(7):126-128. doi:10.3969/j.issn.1001-8972.2022.07.042.
[24]	魏巍, 张慧颖. 嵌入式服务理念下高校科研管理核心服务能力建设. 科技管理研究, 2017, 37(22):122-127. doi:10.3969/j.issn.1000-7695.2017.22.017.